Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

05-03-2026(Thu) 04-03-2026(Wed) 03-03-2026(Tue) 02-03-2026(Mon) 27-02-2026(Fri)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
21 Apr, 2026 (Tuesday)

            
INSILICO(3696)
Analysis¡G
InSilico is primarily engaged in drug discovery and pipeline development, software solutions, and other discoveries in non-pharmaceutical fields by utilizing a generative artificial intelligence platform. The Group has leveraged its self-developed generative AI platform, Pharma.AI, to build a robust R&D pipeline covering fibrosis, oncology, immunology, metabolism, anti-pain, and other therapeutic areas. The Group¡¦s unique ¡§dual-engine¡¨ business model combines the generative AI platform with deep in-house drug discovery capabilities, enabling continuous reinforcement learning that continuously enhances the capabilities of Pharma.AI and drives scientific innovation.Using Pharma.AI, on average, it takes only 12 to 18 months from target discovery to PCC (Preclinical Candidate) confirmation, which is significantly shorter than the traditional method (which takes an average of 4.5 years). The Group is also expanding the application of Pharma.AI to multiple industries, including advanced materials, agriculture, nutritional products, and veterinary drugs.
Pharma.AI consists of Biology42, Chemistry42, Medicine42, and Science42. It is an AI-driven drug discovery and development platform that provides end-to-end services ranging from novel target identification to small molecule generation and clinical outcome prediction, aiming to cover the entire drug discovery and development process.Through Pharma.AI, the Group has generated more than 20 assets that have reached the clinical or IND (Investigational New Drug) application stage. Of these, seven assets have been licensed to or collaborated with pharmaceutical and healthcare companies, with a total contract value of up to US$2.174 billion, including upfront payments of up to US$130 million and milestone payments of up to US$2.044 billion. Since 2021, the total contract value of the Group¡¦s major out-licensing, co-development, and research collaboration agreements has exceeded US$4.6 billion.
The Group¡¦s ¡§AI + Drug Discovery¡¨ dual-engine model achieved solid results in business development in 2025 and early 2026. It has established high-value partnership relationships with leading multinational pharmaceutical companies and top Chinese biopharmaceutical companies. The total value of newly signed business development transactions exceeded US$1.3 billion. In terms of out-licensing, the Group entered into a major agreement with TaiGen Biotechnology, granting it the exclusive rights to develop and commercialize ISM4808 in Greater China. It has also reached research collaborations with Eli Lilly, Servier, Tenacia Biotechnology, China Medical System Holdings Limited and Qilu Pharmaceutical Group, covering multiple therapeutic areas. To accelerate the development of promising candidates, the Group also entered into a strategic co-development agreement with Hygtia Therapeutics to advance ISM8969 (an AI-powered, brain-penetrant NLRP3 inhibitor for the treatment of Parkinson¡¦s disease).(I do not hold the above stock.)
Strategy¡G
Buy-in Price: $67.00, Target Price: $75.00, Cut Loss Price: $63.00


NONGFU SPRING(9633)
Analysis¡G
As a leading enterprise in China's beverage industry, Nongfu Spring demonstrates strong potential through its dominant market position in packaged water and tea beverages, along with continuous product innovation and channel optimization. The company possesses nationally leading water resources and over 3 million retail outlets, forming a robust channel and brand moat. In 2025, the company reported revenue of 52.622 billion yuan, a yoy increase of 22.5%; net profit attributable to the parent company was 15.87 billion yuan, up 30.9% yoy. Benefiting from the decline in raw material costs, both gross margin and net profit margin improved. Additionally, Nongfu Spring reduced costs and enhanced efficiency through large-scale production, achieving a return on equity (ROE) of 40.2%. Future highlights include the continued expansion of the sugar-free tea market, a rebound in the packaged water business share, the development of emerging categories such as NFC juice and iced tea, and the advancement of internationalization strategies.
Strategy¡G
Buy-in Price: $47.74, Target Price: $54.50, Cut Loss Price: $44.00



Geely (175 HK) - Accelerating Overseas Expansion and Premiumisation Strategy

Company Profile

Geely is one of the leading enterprises in China's self-brand passenger vehicles manufacturers. The Company's products include six major brands, Geely, Lynk & Co, Zeekr, covering the A0 to C-class passenger vehicles market.

Investment Summary

26Q1 Sales Remained Largely Flat, with Premiumisation Strategy Showing Bright Spots. In the first quarter of 2026, Geely Auto delivered a cumulative 709.4 thousand vehicles, up 0.8% yoy, setting a new record high for the same period in history and regaining the top position among domestic brands. Among them, Geely brand's China Star recorded Q1 sales of 312 thousand units, down 5.5% yoy, while Galaxy sold 239 thousand units, down 8.0% yoy.

Among the sub-brands, the premium brands delivered standout performance: LYNK&CO sold 82 thousand units, up 12.5% yoy, while Zeekr sold 77 thousand units, up 86.1% yoy. The premium SUV model Zeekr 9X achieved a smooth ramp-up, with cumulative Q1 sales exceeding 20 thousand units and March sales surpassing 10 thousand units. It is the Company's first full-size premium SUV equipped with Super Hybrid technology, and also the first to feature the SEA AI Digital Chassis and the G-Pilot H9 intelligent assisted driving system.

With an average selling price of over RMB 530 thousand, it has significantly enhanced brand strength and the profitability potential following scale-up. We believe that the launch of flagship 9-series models, such as the LYNK&CO 900, Zeekr 9X and Galaxy M9, marks the beginning of a new chapter in the Company's premiumisation strategy in the SUV segment.

Explosive Growth in Exports

In overseas markets, Geely Auto recorded cumulative exports of 203 thousand units in Q1, up 125.7% yoy, far exceeding the industry's average growth rate of 56.7%, representing explosive growth and accounting for 28.6% of total sales. In the European market, the Company has completed brand layout in five core countries¡XSpain, Germany, the Netherlands, Belgium and Luxembourg. In the Southeast Asian market, Geely Xingyuan has commenced deliveries and is gradually advancing localised production.

In Latin America and the Middle East, the LYNK&CO and Zeekr brands are accelerating market penetration. The Company has provided 2026 full-year export sales guidance of no less than 640 thousand units, with a target of 750 thousand units, equivalent to yoy growth of 52.4% to 78.6%. Export business is expected to become the most important growth driver this year.

We believe that the rapid volume expansion and high profitability of overseas markets will help offset the slowdown in domestic sales and improve profit margins.

New Energy Vehicles Account for Over Half

Geely Auto's new energy transition is entering an accelerated phase. In Q1 2026, the Company's cumulative sales of new energy vehicles reached 369.1 thousand units, up 9% yoy, with the penetration rate rising to 52%, and further increasing to 55% in March alone. From a structural perspective, plug-in hybrid models contributed more incremental growth within Geely's new energy product portfolio, up 62% yoy and currently accounting for 44%, while pure electric models declined by 13% yoy, accounting for 56%.

Recent geopolitical conflicts in the Middle East have led to volatility in oil prices, which has objectively accelerated the global adoption of electric vehicles. In the long term, this trend benefits leading automakers with advantages in products, technology, cost, and supply chains. The Company's new energy vehicle segment is expected to achieve a favourable trajectory of simultaneous volume and profit growth.

Strong Performance Last Year, Core Net Profit up 36%

According to the Company's 2025 annual report, full-year revenue reached RMB 345,232 million, up 25.1% yoy; net profit attributable to the parent company was RMB 16,852 million, up 0.2% yoy. Excluding foreign exchange gains, impairment losses, and gains from the deemed disposal of subsidiaries in 2024, core net profit attributable to the parent company amounted to RMB 14.41 billion, up 36% yoy.

The strong performance was mainly driven by robust sales growth, which led to the release of scale effects, as well as optimisation of product mix and synergies from strategic integration. In 2025, the Company recorded cumulative sales of 3,024.6 thousand units, up 39.0% yoy, of which new energy vehicle sales reached 1,687.8 thousand units, up 90.0% yoy. Gross margin in 2025 was 16.61%, up 0.1 ppts yoy; core net profit margin attributable to the parent company increased to 4.2%, up 0.5 ppts yoy.

The rising sales mix of Zeekr contributed significantly to the improvement in overall gross margin. In terms of expense ratios, the sales/administration/R&D expense ratios were 5.92%/1.88%/5.1%, respectively, representing yoy changes of -0.04/-0.39/+0.14 ppts. This was mainly due to increased investment in the R&D of new models and platforms, as well as a lower capitalisation ratio of R&D expenses.

Looking ahead, as the One Geely strategy continues to deepen, the cost reduction effect from declining expense ratios¡Xdriven by technology sharing and cost optimisation¡Xwill continue to materialise.

Investment Thesis

We revised our financial forecast and target price to HKD 26.6, equivalent to 12.5/10.8/8.4x PE ratio in 2026/2027/2028, and we give the rating of Accumulate. Closing price as at 15 April.

Geely's PE Band trend

""

Source: Wind, Company, Phillip Securities Hong Kong Research

Financial

"Financial

(Closing price as at 15 April)


Download PDF version...




Recommendation on 21-4-2026
RecommendationAccumulate
Price on Recommendation Date$ 24.040
Suggested purchase priceN/A
Target Price$ 26.600
Writer Info
Zhang Jing
(Analyst)
Tel: + 86 021-6351 2939
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2026 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]